Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,999 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the completion of the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. This trade represents a 41.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.75, for a total value of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total transaction of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.

Oruka Therapeutics Stock Performance

Shares of ORKA traded down $2.16 during mid-day trading on Tuesday, reaching $78.19. The stock had a trading volume of 490,798 shares, compared to its average volume of 1,091,331. The firm has a market cap of $5.18 billion, a price-to-earnings ratio of -38.52 and a beta of -0.37. Oruka Therapeutics, Inc. has a 12 month low of $24.88 and a 12 month high of $115.51. The business has a fifty day moving average of $94.29 and a 200 day moving average of $79.41.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wedbush set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 24th. UBS Group lifted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $128.91.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Sei Investments Co. increased its position in Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after acquiring an additional 13,164 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $2,874,000. Dimensional Fund Advisors LP bought a new stake in shares of Oruka Therapeutics in the 1st quarter worth about $5,543,000. Handelsbanken Fonder AB purchased a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $15,313,000. Finally, Palo Alto Investors LP purchased a new stake in Oruka Therapeutics in the 2nd quarter worth about $3,192,573. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.